FetaLink+ vs ASCCP Management Guidelines

With FetaLink+, surveillance information that is available at the bedside can be accessed from any location through an iOS mobile device with either cellular or WiFi connectivity, driving efficiency at the point of care. Application functionality: • Provides comprehensive patient list • Displays most recent key obstetrical data, including ruptured membrane, gravida para, and cervical exam • Displays both fetal and maternal monitoring waveform data • Allows Providers to review all monitoring data from the current episode • Fetal tracing can be viewed when user is in the annotation summary view • Ability to view both clinician and device annotations at relevant times on the strip • Ability to view Medication and IV administration annotations on the strip • Ability to view annotations made by the bedside clinician • Ability to view maternal vital signs captured from the fetal monitor FetaLink+ is a diagnostic aid that does not replace the clinician’s judgment concerning interpretation of data or appropriate treatment. FetaLink+ requires that the care organization license and operate infrastructure for use. Please contact your corporate IT or Cerner representative for details or inquiry.

The ASCCP Risk-Based Management Consensus Guidelines provide evidence-based recommendations for managing abnormal cervical cancer screening results and cancer precursors, including post-colposcopy and post-treatment scenarios. ASCCP is pleased to offer this app to streamline navigation of the ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. The guidelines articles, as published in the Journal of Lower Genital Tract Disease, as well as the comprehensive risk estimates, can be accessed through https://www.asccp.org/guidelines. These evidence-based management guidelines, initially developed in 2019, came together through a consensus process of 19 organizations. The updated management guidelines aim to: • Allow for a more complete and precise estimation of risk • Provide more appropriate intervention for high-risk individuals (detect and treat more precancer) • Recommend less intervention for low-risk individuals (decrease testing and treatment that won’t prevent cancer and may cause reproductive harm) • Allow for the future addition of new risk modifiers and screening and management technologies See https://www.asccp.org/UserGuide for tips on using the app.